Skip to main content

Gilead Sciences guidance

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

In its results release of 29 Oct 2026 (Q3 FY2026), Gilead Sciences gave 1 forecast in figures, among them tax rate (adjusted) of 21% for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
Tax rate · AdjustedFY202621%GAAP projected effective tax rate 21%

Source: the company's earnings release.

Guidance against results above 1 · within 1 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
EPSFY2026−$3.25 to −$2.85Lowered once—To come
EPS · AdjustedFY2026−$1.05 to −$0.65Given once—To come
Tax rate · AdjustedFY202621%Unchanged—To come
EPS · AdjustedFY2025$8.05 to $8.25Raised twice$8.15Within the range
EPS · AdjustedFY2024$4.25 to $4.45Given once$4.62Above the range

GILD in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.